3-Amino-7-phthalazinylbenzoisoxazoles as a Novel Class of Potent, Selective, and Orally Available Inhibitors of p38α Mitogen-Activated Protein Kinase

Citations Over TimeTop 20% of 2008 papers

Abstract

The p38 mitogen-activated protein kinase (MAPK) is a central signaling molecule in many proinflammatory pathways, regulating the cellular response to a multitude of external stimuli including heat, ultraviolet radiation, osmotic shock, and a variety of cytokines especially interleukin-1beta and tumor necrosis factor alpha. Thus, inhibitors of this enzyme are postulated to have significant therapeutic potential for the treatment of rheumatoid arthritis, inflammatory bowel disease, osteoporosis, and many other diseases where aberrant cytokine signaling is the driver of disease. Herein, we describe a novel class of 3-amino-7-phthalazinylbenzoisoxazole-based inhibitors. With relatively low molecular weight, these compounds are highly potent in enzyme and cell-based assays, with minimal protein shift in 50% human whole blood. Compound 3c was efficacious (ED 50 = 0.05 mg/kg) in the rat collagen induced arthritis (CIA) model.

Related Papers

• → Influence of aging and calorie restriction on MAPKs activity in rat kidney(2002)74 cited
• → Teratogen‐induced activation of ERK, JNK, and p38 MAP kinases in early postimplantation murine embryos(2000)2 cited
• → Uniaxial Stretch-Induced Regulation of Mitogen Activated Protein Kinase (MAPK) phosphorylation in Aging Rat Aorta(2006)
• p38 MAPK involves in cepharanthine -induced apoptosis in cardiomyocytes(2011)
• → Effect of Angiotensin III on ERK1/2 and p38 mitogen activated protein (MAP) kinases in Wistar rat VSMCs(2015)